Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults.

IF 2.7 3区医学 Q2 HEMATOLOGY Current Hematologic Malignancy Reports Pub Date : 2022-12-01 Epub Date: 2022-09-19 DOI:10.1007/s11899-022-00680-6

Ginna Granroth, Nandita Khera, Cecilia Arana Yi

{"title":"Progress and Challenges in Survivorship After Acute Myeloid Leukemia in Adults.","authors":"Ginna Granroth, Nandita Khera, Cecilia Arana Yi","doi":"10.1007/s11899-022-00680-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: Acute myeloid leukemia (AML) survivors face unique challenges affecting long-term outcomes and quality of life. There is scant literature on the long-term impact of AML treatment in physical and mental health, disease recurrence, and financial burden in survivors.Recent findings: Fatigue, mental health concerns, infections, sexual dysfunction, and increase cancer recurrence occur after AML treatment. Chronic graft-versus-host disease (GVHD) and infections are common concerns in AML after hematopoietic stem cell transplantation (HCT). Survivorship guidelines encompass symptoms and complications but fail to provide an individualized care plan for AML survivors. Studies in patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are sparse. Here we discuss the most common aspects pertaining to AML survivorship, late complications, care delivery, prevention of disease recurrence, and potential areas for implementation.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"17 6","pages":"243-253"},"PeriodicalIF":2.7000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483315/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-022-00680-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Acute myeloid leukemia (AML) survivors face unique challenges affecting long-term outcomes and quality of life. There is scant literature on the long-term impact of AML treatment in physical and mental health, disease recurrence, and financial burden in survivors.

Recent findings: Fatigue, mental health concerns, infections, sexual dysfunction, and increase cancer recurrence occur after AML treatment. Chronic graft-versus-host disease (GVHD) and infections are common concerns in AML after hematopoietic stem cell transplantation (HCT). Survivorship guidelines encompass symptoms and complications but fail to provide an individualized care plan for AML survivors. Studies in patient-reported outcomes (PROs) and health-related quality of life (HRQoL) are sparse. Here we discuss the most common aspects pertaining to AML survivorship, late complications, care delivery, prevention of disease recurrence, and potential areas for implementation.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

成人急性髓性白血病患者生存期的进展与挑战

综述目的：急性髓性白血病（AML）幸存者面临着影响长期治疗效果和生活质量的独特挑战。有关急性髓性白血病治疗对幸存者身心健康、疾病复发和经济负担的长期影响的文献很少：最近的发现：急性髓细胞性白血病治疗后会出现疲劳、精神健康问题、感染、性功能障碍以及癌症复发率上升。慢性移植物抗宿主疾病（GVHD）和感染是急性髓细胞性白血病造血干细胞移植（HCT）后常见的问题。生存指南包括症状和并发症，但未能为急性髓细胞性白血病幸存者提供个体化护理计划。有关患者报告结果（PROs）和健康相关生活质量（HRQoL）的研究很少。在此，我们将讨论与急性髓细胞性白血病幸存者、晚期并发症、护理服务、疾病复发预防以及潜在实施领域相关的最常见问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.